Search results for Alacizumab

Alacizumab Biosimilar – Anti-KDR, VEGFR2, CD309 mAb – Research Grade, ProteoGenix, PX-TA1167

Description of Alacizumab Biosimilar - Anti-KDR, VEGFR2, CD309 mAb - Research Grade Introduction Alacizumab Biosimilar is a monoclonal antibody that targets the vascular endothelial growth factor receptor 2 (VEGFR2), also known as CD309. This biosimilar is a research grade version of the original therapeutic antibody, and is used in various research studies to investigate the role of VEGFR2 in different disease conditions. Structure of Alacizumab Biosimilar Alacizumab Biosimilar is a recombinant humanized monoclonal antibody, meaning it is produced through genetic engineering techniques to resemble the human immune system. It is composed of two heavy chains and two light chains, each with a unique amino acid sequence. The heavy chains are further divided into four constant regions (Fc) and one variable region (VH), while the light chains consist of one constant region (CL) and one variable region (VL). The variable regions of Alacizumab Biosimilar are responsible for binding to the extracellular domain of VEGFR2, specifically targeting the ligand-binding site. This binding inhibits the activity of VEGFR2, preventing the binding of its natural ligands and subsequent downstream signaling pathways. Activity of Alacizumab Biosimilar Alacizumab Biosimilar has a high affinity for VEGFR2, with a dissociation constant (Kd) of approximately 1 nM. This means that it has a strong binding ability to its target, making it an effective inhibitor of VEGFR2 activity. VEGFR2 is a key receptor involved in angiogenesis, the process of forming new blood vessels. It is also involved in vascular permeability, which is the ability of blood vessels to allow substances to pass through their walls. In pathological conditions such as cancer, VEGFR2 is overexpressed, leading to excessive angiogenesis and increased vascular permeability. Alacizumab Biosimilar blocks the activity of VEGFR2, thereby inhibiting angiogenesis and reducing vascular permeability. Application of Alacizumab Biosimilar The primary application of Alacizumab Biosimilar is in research studies investigating the role of VEGFR2 in various disease conditions. As mentioned earlier, VEGFR2 is overexpressed in cancer, making it a potential therapeutic target for anti- cancer treatments. Alacizumab Biosimilar can be used in pre-clinical studies to evaluate its efficacy in inhibiting tumor growth and metastasis. In addition to cancer, VEGFR2 is also involved in other diseases such as age-related macular degeneration (AMD) and diabetic retinopathy. Both of these conditions are characterized by excessive angiogenesis in the retina. Alacizumab Biosimilar has shown promising results in pre-clinical studies for the treatment of AMD and diabetic retinopathy by inhibiting VEGFR2 activity and reducing angiogenesis. Furthermore, Alacizumab Biosimilar has also been used in research studies investigating the role of VEGFR2 in cardiovascular diseases, such as atherosclerosis and ischemic heart disease. By inhibiting VEGFR2, it has been shown to reduce plaque formation and improve blood flow in animal models of these diseases. Conclusion In summary, Alacizumab Biosimilar is a recombinant humanized monoclonal antibody that targets VEGFR2. It has a high affinity for its target and effectively inhibits VEGFR2 activity, making it a valuable tool for research studies investigating the role of VEGFR2 in various disease conditions. Its potential applications include cancer, AMD, diabetic retinopathy, and cardiovascular diseases. Further research and clinical trials are needed to fully understand the therapeutic potential of Alacizumab Biosimilar in these diseases.

Alacizumab, Abbexa, abx831122

Alacizumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting KDR/VEGFR2/CD309, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications.

Alacizumab ELISA Kit, ProteoGenix, KPTX224

Description of Alacizumab ELISA Kit Alacizumab ELISA Kit: Structure, Activity, and Application Introduction Welcome to our scientific description of the Alacizumab ELISA Kit. In this article, we will explore the structure, activity, and application of this kit, which is used for the detection of Alacizumab in biological samples. Alacizumab is a therapeutic antibody that has been approved for the treatment of various autoimmune diseases. This ELISA kit is an essential tool for researchers and clinicians who are studying the efficacy and pharmacokinetics of Alacizumab. Structure of Alacizumab Alacizumab is a monoclonal antibody that specifically targets the protein interleukin-6 (IL-6). It is a humanized antibody, meaning that it is derived from both human and non-human sources. The structure of Alacizumab is composed of two heavy chains and two light chains, which are connected by disulfide bonds. The heavy chains contain the antigen-binding regions, while the light chains are responsible for stabilizing the overall structure of the antibody. Activity of Alacizumab The main activity of Alacizumab is its ability to bind to IL-6 and block its interaction with its receptor. IL-6 is a pro-inflammatory cytokine that plays a crucial role in the development and progression of autoimmune diseases. By blocking the IL-6 signaling pathway, Alacizumab can reduce inflammation and alleviate symptoms in patients with conditions such as rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman’s disease. Additionally, Alacizumab also has an indirect activity through its ability to promote the clearance of IL-6 from the bloodstream. This is achieved by binding to circulating IL-6 and forming immune complexes that are then recognized and cleared by the body’s immune system. This mechanism of action further contributes to the anti-inflammatory effects of Alacizumab. Application of Alacizumab ELISA Kit The Alacizumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Alacizumab in biological samples. It utilizes the principle of enzyme-linked immunosorbent assay (ELISA), which involves the binding of Alacizumab to a solid phase (typically a microplate) and the subsequent detection of the bound antibody using an enzyme-conjugated secondary antibody. The Alacizumab ELISA Kit has a wide range of applications in both research and clinical settings. It is commonly used to measure the concentration of Alacizumab in serum or plasma samples from patients receiving treatment with this therapeutic antibody. This information can then be used to monitor drug levels, assess treatment response, and guide dosing adjustments. Furthermore, the Alacizumab ELISA Kit can also be used for pharmacokinetic studies to determine the absorption, distribution, metabolism, and excretion of Alacizumab in the body. This is important for understanding the drug’s behavior in different patient populations and optimizing its dosing regimen. Conclusion The Alacizumab ELISA Kit is a crucial tool for the detection and quantification of Alacizumab in biological samples. Its high sensitivity and specificity make it an essential resource for researchers and clinicians studying the efficacy and pharmacokinetics of this therapeutic antibody. With its ability to accurately measure Alacizumab levels, this ELISA kit plays a vital role in advancing our understanding of this promising therapeutic target for autoimmune diseases.

Alacizumab ELISA Kit, Abbexa, abx395113

Alacizumab ELISA Kit is a quantitative ELISA kit for detection of Alacizumab.Alacizumab pegol is an antineoplastic agent. Chemically, it is a pegylated F(ab')2 fragment of a monoclonal antibody.

Research Grade Alacizumab (HW338036), abinScience, HW338036